Skip to Content

Telotristat Dosage

Medically reviewed on March 30, 2017.

Applies to the following strengths: 250 mg

Usual Adult Dose for Carcinoid Tumor

250 mg orally 3 times a day

Comments:
-Patients should take this drug with food.
-If needed, short-acting octreotide should be given at least 30 minutes after administration of this drug.
-Patients should discontinue use if severe constipation occurs.

Use: Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in patients whose diarrhea is inadequately controlled by SSA therapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Patients who miss a dose should take the next dose at the regular time; taking 2 doses at the same time should be avoided.

Monitoring:
-Signs/symptoms of severe constipation

Patient advice:
-Patients should be told to immediately report signs/symptoms of severe constipation or worsening abdominal pain.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide